Leidos' Q3 Earnings Beat Estimates, Revenues Miss, '26 EPS View Raised

Leidos reported Q3 2026 adjusted EPS of $3.62, up 18.7% year over year and 19.1% above estimates, while revenue rose 3.6% to $4.63B but missed consensus by 1.6%. It raised 2026 adjusted EPS guidance to $12.50-$12.70 and operating cash flow guidance to nearly $1.9B, but lowered its revenue outlook to $18.00-$18.20B from $18.20-$18.40B. Q3 operating cash flow fell to $523M from $711M, while the company returned $556M through $504M in buybacks and $52M in dividends.

Analysis

The earnings beat is less durable than the EPS headline suggests: near-flat organic growth, lower revenue guidance, and weaker quarterly operating cash flow/free cash flow point to conversion and timing risk. Higher EPS guidance alongside lower sales guidance implies management expects better earnings conversion, but buybacks also amplify per-share results; test this against subsequent operating performance rather than extrapolating the beat. Rising debt and lower cash make sustained repurchases more consequential if cash generation disappoints.

The backlog mix is a useful counterweight, not a near-term revenue guarantee. Funded backlog growth supports visibility, while the much larger unfunded balance leaves conversion exposed to appropriations, customer timing, and contract execution. Homeland’s growth is partly acquisition-supported, so reported momentum may overstate underlying acceleration; Health’s revenue and margin declines expose a separate drag that strong Homeland margins do not fully offset. Defense demand and intelligence awards are supportive, but modest segment growth limits the case for broad-based acceleration.

Near term, a positive EPS reaction could obscure the revenue miss; without price/positioning data, do not assume the beat is underpriced. Over 1–3 months, the key catalysts are cash conversion and evidence that organic growth stabilizes. Over 6–18 months, backlog conversion and the durability of acquisition-led infrastructure demand matter most. The thesis improves if organic growth and free cash flow recover; it weakens if revenue guidance is cut again, funded backlog stalls, or repurchases remain elevated while cash generation declines.

Key Decisions for Investors

• Avoid chasing LDOS solely on the EPS beat; treat the setup as neutral-to-cautious until the market reaction and valuation are assessed against the lower revenue outlook and soft cash conversion.
• For an existing position, monitor quarterly organic revenue, funded backlog/book-to-bill, and operating cash flow versus the raised annual outlook. Reassess if funded backlog weakens or another revenue-guidance reduction arrives.
• Do not underwrite Homeland’s reported growth as wholly organic: verify ENTRUST contribution and organic segment growth in the next update. A slowdown in underlying demand would make the acquisition-led growth narrative less supportive.
• Use recovery in Health revenue and margin, alongside improving free cash flow, as thesis-confirmation signals; persistent deterioration would falsify the view that EPS growth reflects durable operating improvement.